Fully integrated drug discovery platform brought to you by 4SC Discovery and Crelux
Get the best candidates through the best service, fast
i2c (idea to candidate) is an integrated drug discovery platform formed by the two companies 4SC Discovery and Crelux, working together under one roof in a strategic alliance. i2c offers a seamless process from early concept through to a preclinical development candidate ready to advance into formal animal model testing and thereafter into clinical trials.
We offer our services to pharma companies looking to outsource part of their early discovery projects and also small and mid-size biotech companies lacking the relevant technologies or infrastructure.
Besides the standard fee-for service offerings i2c also includes research collaborations based on tailor made risk sharing models.
The i2c approach is based on a unique combination of skills, technology and track record. 4SC Discovery is one of the “groundbreakers” for industrialized in silico screening, and over 250 targets have already been screened with this platform. The strong computational chemistry competence of 4SC is complemented by CRELUX, a global leader in protein crystallography and biophysical compound screening, harboring the world’s largest collection of readily available crystallography targets (>125).
i2c - a perfect suite of drug discovery technologies with a significant track record:
- 90% successful hit finding programs, projects up to clinical phase 2 are based on this discovery platform
- numerous proprietary software tools for in silico screening and computational chemistry developed in house
- our structure based in silico approach grants low project start hurdles/cost
- the i2c in vitro screening platform has no limitations regarding target class and integration of client compounds
As a technology and know how leader in the market for early-stage pharmaceutical research, we can draw from our vast experience in providing discovery services to pharma customers and have a global client base of more than 150 companies.
Benefit from our expertise!
Press release: CRELUX and 4SC Discovery awarded research grant for new epigenetic cancer drugs
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme
Planegg-Martinsried, Germany, 24 July 2014 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that its subsidiary 4SC Discovery GmbH, which specialises in the discovery and early-stage research of new substances, has been awarded a research grant for the discovery and identification of new epigenetic anti-cancer compounds in collaboration with its strategic cooperation partner CRELUX GmbH. A joint research project between 4SC Discovery and CRELUX initially running for eleven months will receive funding under the Munich m4 biotech cluster programme. It will focus on the identification of bromodomain inhibitors and their possible later use in personalised medicine.
Press Release: AiCuris, 4SC Discovery and CRELUX announce drug discovery collaboration
AiCuris will use the high quality integrated drug discovery platform i2c of CRELUX and 4SC Discovery to identify novel therapeutics for infectious diseases
Planegg-Martinsried and Wuppertal, Germany, 4 November 2013 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs mainly focusing on cancer and autoimmune diseases, today announced that 4SC Discovery GmbH, CRELUX GmbH and AiCuris GmbH & Co. KG have started a drug discovery collaboration to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases. The collaboration is a further proof for the innovative capacity and the high quality standard of the joint integrated drug discovery platform i2c (“idea-to-candidate”), operated by 4SC Discovery and CRELUX.
Press Release: UCB to collaborate with CRELUX and 4SC Discovery to meet unmet needs in neurology.
Planegg-Martinsried, Germany and Brussels, Belgium, 11 June 2013 –4SC AG today announced that CRELUX GmbH, 4SC Discovery GmbH and UCB have started a drug discovery collaboration to identify and validate novel small molecule compounds for the treatment of neurological disorders. This collaboration fits perfectly into UCB’s strategy of building a global network of partnerships in order to bring innovative solutions to patients living with severe diseases.